CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT01984346

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01984346
Other papers using this trial's data
  • Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial Circulation. Arrhythmia and electrophysiology, 2020-12 DOI, PubMed 33185144

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01984346. Randomized; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2019-08 (actual). Results posted on 2022-02-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
Acronym
CONVERGE
Condition
Persistent Atrial Fibrillation
Intervention (Device)
AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax
Intervention (Device)
Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
Lead sponsor
AtriCure, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01984346
Content hash
2d31a6c264d6613550bb478a7ada165802ef2f29e43d6acb6ef9ed9b293ee24c